Search clinical trials for: deletion 5q

Total 334 results

National Cancer Institute (NCI)

Not yet recruiting

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes

United States
University Hospital, Brest

Recruiting

Biocollection in MyeloDysplastic Syndrome (P-MDS) (P-MDS)

Myelodysplastic Syndromes | Chromosome Abnormality | Acute Myeloid Leukemia With Multilineage Dysplasia | Myelodysplastic Syndrome With Ring Sideroblasts | Myelodysplastic Anemia | Myelodysplastic Syndrome With Isolated Del(5Q)

France
Simons Searchlight
Boston Children's Hospital; Geisinger Clinic; Simons Foundation

Recruiting

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

SMARCA4 Gene Mutation | DDX3X | 16P11.2 Deletion Syndrome | 16p11.2 Duplications | 1Q21.1 Deletion | 1Q21.1 Microduplication Syndrome (Disorder) | ACTL6B | ADNP | AHDC1 | ANK2 | ANKRD11 | ARID1B | ASH1L | BCL11A | CHAMP1 | CHD2 | CHD8 | CSNK2A1 | CTBP1 | CTNNB1 Gene Mutation | CUL3 | DNMT3A | DSCAM | DYRK1A | FOXP1 | GRIN2A | GRIN2B | HIVEP2-Related Intellectual... and other conditions

United States
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (MDS-LE-MON-5)

Myelodysplastic Syndromes

Germany
Celgene

Completed

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea (RevlimidPMS)

Lymphoma, Follicular | Myelodysplastic Syndromes | Lymphoma, Mantle-Cell

Korea, Republic of
Fundación General de la Universidad de Salamanca
Celgene Corporation

Completed

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (SINTRA-REV)

Myelodysplastic Syndrome

Germany, Spain, France
Celgene

Completed

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Myelodysplastic Syndromes

United States, Germany
Celgene

Completed

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry (MORE)

Myelodysplastic Syndrome

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Myelodysplastic Syndrome

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene Corporation

Terminated

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome | MDS | Low to Intermediate-1 MDS | Non-deletion 5q

United States
Asociación Andaluza de Hematología y Hemoterapia

Completed

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)

Myelodysplastic Syndrome (MDS)

Spain
Groupe Francophone des Myelodysplasies
Celgene Corporation

Unknown

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (GFM-Chimio-Rev)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

France
Telik

Terminated

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Telik

Terminated

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Telik

Completed

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Celgene Corporation
ICON Clinical Research

Completed

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Myelodysplastic Syndromes

Germany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
National Institutes of Health Clinical Center (CC)

Completed

Leucovorin for the Treatment of 5 q Minus Syndrome

Myelodysplastic Syndrome | 5q Minus Syndrome

United States
Groupe Francophone des Myelodysplasies

Unknown

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Myelodysplastic Syndromes

France
InSilico Medicine Hong Kong Limited

Not yet recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Umraniye Education and Research Hospital

Recruiting

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

Preterm Birth | Fetal Growth Retardation | Preeclampsia | Gestational Diabetes | Gestational Hypertension

Turkey
Amgen

Recruiting

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

United States
Heartfelt Technologies

Not yet recruiting

Randomised Controlled Trial for Assessing the Effectiveness of an Inclusive Heart Failure Monitoring and TRACKing Solution in the UK. (HF-TRACK)

Heart Failure

United Kingdom
Amgen

Recruiting

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Non-small Cell Lung Cancer | Thoracic Tumors

United States
M.D. Anderson Cancer Center
Aadi Bioscience

Not yet recruiting

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Leiomyosarcoma | Soft-tissue Sarcomas

United States
Baylor College of Medicine
Doris Duke Charitable Foundation

Recruiting

Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders

RAI1 Gene 17P11.2 Deletion+Duplication

United States
Heartfelt Technologies

Not yet recruiting

The HEARTFELT Study (HEARTFELT)

Heart Failure
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene

MTAP-deleted Solid Tumors

Australia, United States
University of British Columbia

Not yet recruiting

Vitamin B12 and Folinic Acid Supplementation in Mitochondrial DNA Deletion Syndromes

Mitochondrial DNA Deletion | Macrocytosis
Anagnostou, Evdokia, M.D.
The Hospital for Sick Children; Canadian Institutes of Health Research (CIHR); Alberta Health services and other collaborators

Not yet recruiting

Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders (CALM)

Anxiety Disorders | Generalized Anxiety Disorder | Anxiety | Tuberous Sclerosis | ADHD | Neurodevelopmental Disorders | Autism Spectrum Disorder | Fragile X Syndrome | Social Anxiety | Social Anxiety Disorder | Agoraphobia | Tourette Syndrome | Tic Disorders | Autism | ADHD Predominantly Inattentive Type | ADHD - Combined... and other conditions

Canada
University of Utah

Recruiting

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion (BORXPTEN)

Metastatic Castration-resistant Prostate Cancer

United States
Centro de Tratamiento e Investigación sobre Cáncer...

Not yet recruiting

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) (CULTRO)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 Mutation

Colombia
Associazione Qol-one

Recruiting

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD (Phoenix)

Myelodysplastic Syndromes | Anemia | Transfusion-dependent Anemia | Del(5Q)

Italy
UMC Utrecht
Eindhoven University of Technology

Recruiting

Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development (EARLYBIRD)

22q11.2 Deletion Syndrome | Adolescent Idiopathic Scoliosis

Netherlands
Innovation Research & Training

Recruiting

Mindfulness Program for Adolescents With 22q11DS

22Q11 Deletion Syndrome

United States
Laboratoires Vivacy

Recruiting

Study of a Novel Hyaluronic Acid Based Gel for Volume Deficiency in the Mid-face (FaceHyal) (FaceHyal)

Aging | Aesthetics | Volume Deficiency in the Mid-Face

France
Tango Therapeutics, Inc.

Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Locally Advanced Solid Tumor

United States, Spain, France
University Hospital Schleswig-Holstein
Michael J. Fox Foundation for Parkinson's Research

Recruiting

Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes (SensoMo-PD)

Dystonia | Parkinson | Dystonia, Familial | DYT3 | DYT5 | PINK1 Gene Deletion

Germany
Novartis Pharmaceuticals

Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma

Korea, Republic of
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
Stephan Eliez

Recruiting

Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome

tACS | 22Q11 Deletion Syndrome

Switzerland
Cristina Domínguez González

Recruiting

Natural History in Primary Mitochondrial Myopathies (NHPMM)

Primary Mitochondrial Myopathies

Spain
Hoffmann-La Roche

Recruiting

Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (Aldebaran)

Angelman Syndrome

United States, Australia, Spain, Italy, France, Germany
Novartis Pharmaceuticals

Recruiting

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (SPECTRUM)

Spinal Muscular Atrophy (SMA)

Spain, Canada, Taiwan, Belgium, Malaysia, China, Japan, Italy, Singapore, United Kingdom, France, Australia, Thailand, Denmark, United States
Sumitomo Pharma Switzerland GmbH

Recruiting

Congenital Athymia Patient Registry

Complete DiGeorge Anomaly | Complete DiGeorge Syndrome | Congenital Athymia

United States
Tango Therapeutics, Inc.

Recruiting

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Locally Advanced Solid Tumor

United States, France
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Pancreatic Adenocarcinoma | Solid Tumor | Non Small Cell Lung Cancer | Mesothelioma | Advanced Solid Tumor | Malignant Peripheral Nerve Sheath Tumors

United States
Assiut University
principle investigator

Not yet recruiting

Partial PTEN Deletion in Breast Cancer

PTEN Gene Deletion
The Champ Foundation
Children's Hospital of Philadelphia; The Cleveland Clinic

Recruiting

SLSMDS Natural History Study

Pearson Syndrome | Single Large Scale Mitochondrial DNA Deletion Syndromes (SLSMDS)

United States
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Peking University Third Hospital

Recruiting

Gene Biobank of Sports Injuries

Gene Insertions | Gene Deletion

China

Search clinical trials for: deletion 5q

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations